Angelini Pharma explores acquisition of US-listed Catalyst Pharmaceuticals
Updated
Updated · Bloomberg · Apr 27
Angelini Pharma explores acquisition of US-listed Catalyst Pharmaceuticals
9 articles · Updated · Bloomberg · Apr 27
The Italian drugmaker is working with advisers as it considers purchasing Catalyst Pharmaceuticals Inc., a company listed in the United States.
Discussions are at a preliminary stage and no final decision has been made regarding the potential deal.
Angelini Pharma is seeking to expand its global presence through strategic acquisitions, but details remain confidential and subject to further developments.
As Catalyst's stock soars, what final price will Angelini Pharma pay for its coveted US market entry?
Is Angelini's bid for Catalyst a sign that rare disease drugs are now the safest bet in pharmaceuticals?
With over $700M in cash, should Catalyst reject a buyout and pursue its own acquisition strategy instead?
How will this deal impact the price and availability of critical drugs for rare neurological diseases?
Is Firdapse's patent protection until 2030 enough to secure a multi-billion dollar valuation for Catalyst?